Responsible Regional Contact Point
Organisation:	AWSG - AUSTRIA
Contact person:	Behnoosh Amirimani
Contact details:	b.amirimani@awsg.at +43 1 501 75 - 552
Organisation Details
Founded (Year):	1934
No of employees:	250+
Turnover (US $):	< 250k
Organisation Type:	Company
Company (Organisation) details
The company is a medium-sized independent pharmaceutical company founded in 1934 and is specialised in Formulation development, manufacturing and distribution of conventional and highly active (cytostatic drug) parenterals
Areas of activity:
-  Biology/Biotechnology -  Generic Tools
1) Technology Offer
Formulation and manufacturing of drugs and production of injectables
ABSTRACT: The company is specialised in manufacturing of liquid injectables. Long-standing experience and a special technology provides with the competence of an international, FDA-approved manufacturer of parenteral pharmaceutical dosage forms. The production of highly potent cytotoxic products is carried out in separate areas with product-specific equipment. The company is searching for a technical co-operation for development and production of highly active, parenteral drug formulations. DESCRIPTION: The company is specialised in manufacturing of injectables (ampoules 1-20 ml, vials 1-100 ml). Besides the manufacturing of conventional parenteral drug products the company is specialised in the production of cytotoxic parenterals, a complex process that requires sophisticated expertise and equipment. The production of such highly active products needs special, clearly dedicated equipment and technology. Moreover, special protection measurements for staff and environment are implemented. In the state-of-the-art facility in Austria, clients are accompanied from start to finish, including clinical trials, scaling up, production, filling, and finishing. The production of cytotoxic drugs is carried out in dedicated areas with product-specific equipment. The company has four separate filling lines for vials and ampoules from 1 ml up to 100 ml with capacities of 15 million vials and 100 million ampoules per year. As a medium-sized pharmaceutical company, the company has the necessary flexibility to react rapidly on the specific requirements of clients. Offered services: - Formulation development - Procuring of source and packaging materials - Manufacturing & finishing of parenterals - Quality control & assurance - Storage, distribution and delivery. The company is searching for technical co-operation for development and production of highly active, parenteral drug formulations. INNOVATIVE ASPECTS: The production of highly active drugs needs dedicated equipment and special measurements for staff and environmental protection. The company is one of the few European companies that are approved by the FDA (U. S. Food and Drug Administration) to manufacture cytotoxic and other highly active products. MAIN ADVANTADGES / BENEFITS: The company offers a solution under one roof for: - Formulation development - Stability testing - Dossier compilation - The procuring of all source and packaging materials - Manufacturing & finishing of liquid parenteral products - In-process and release analyses - Storage, distribution and delivery to specified recipients, nationally and internationally As a medium-sized pharmaceutical company, the company has the necessary flexibility to react rapidly on the specific requirements of clients. CURRENT STAGE OF DEVELOPMENT: On the market INTELLECTUAL PROPERTY RIGHTS (IPR): Know How MARKET APPLICATIONS: X License Agreement X Technical Co-operation X Manufacturing agreement/Prototyping X Commercial Agreement with Technical Assistance TYPE OF COLLABORATION SOUGHT: Partner Qualification Criteria & PARTNER PROFILE: The co-operation partner should be a company from the pharmaceutic or the life science sector. Two ways of co-operation are possible: - The co-operation partner delivers a dossier and the company will produce the product, based on the description and the applicable regulations. - The co-operation partner delivers the raw material and the company develops the product in co-operation with the partner.
Market application:
-  HUMAN/ANIMAL HEALTH
Entry/Update:	2006-10-25  /  2007-01-19